# FGFR2 fusion or rearrangement

Source: https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/  
OnCo record `fgfr2-fusion-rearrangement` (Biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FGFR2 fusions occur in 10 to 15 percent of intrahepatic bile duct cancers and almost nowhere else. Pemigatinib and futibatinib are approved for them after a first chemotherapy.

## Summary

FGFR2 fusions (BICC1 is the commonest partner) and other rearrangements are detected by RNA or DNA sequencing or FISH. Pemigatinib (Pemazyre, 2020) is labelled for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test, FoundationOne CDx being the companion diagnostic; futibatinib (Lytgobi, 2022) for intrahepatic cholangiocarcinoma harbouring FGFR2 gene fusions or other rearrangements. Infigratinib's US approval was withdrawn in 2024. Acquired kinase-domain mutations (N550, V565F) drive resistance and are the target of next-generation FGFR2 inhibitors in trials.

## Fields

- Kind: Biomarker
- Last checked: 2026-09-23
- Also known as: FGFR2 fusion; FGFR2 rearrangement; FGFR2-BICC1; FGFR2::BICC1; FGFR2 fusion-positive cholangiocarcinoma; FGFR2 alteration
- Tags: biomarker; fgfr

## Sources

- PEMAZYRE prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e1f2222-1d89-4e63-989c-ccebe2ab1eb4
- LYTGOBI prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b1332a1-0581-4707-9bf6-1eccfa39bef4

## Connected records

- biomarkers: [FGFR3 alteration (mutation or fusion)](https://onco.cc/biomarkers/fgfr3-alteration/)
- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- drugs: [FoundationOne CDx / Liquid CDx](https://onco.cc/drugs/foundationone-cdx/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Infigratinib](https://onco.cc/drugs/infigratinib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/)
- terms: [FGFR2 fusions and rearrangements](https://onco.cc/terms/fgfr2-fusion/), [Gene fusion](https://onco.cc/terms/gene-fusion/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)

---
JSON: https://onco.cc/api/v1/entities/fgfr2-fusion-rearrangement.json